Who is sponsoring NCT03687515?

NCT03687515 is sponsored by Beijing Tongren Hospital.

What drugs are being tested in NCT03687515?

Interventions in NCT03687515: budesonide, budesonide, Prednisone.

What condition does NCT03687515 study?

NCT03687515 studies Chronic Rhinosinusitis With Polyposis.

Is NCT03687515 still recruiting?

NCT03687515 is currently completed. Last updated 27 September 2018.

Last reviewed 2018-09-27 · How we verify

NCT03687515

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Budesonide Inhalation Suspension for the Treatment of Chronic Rhinosinusitis With Polyposis.

Completed Phase 3 Last updated 27 September 2018

What this trial tests

Phase 3 trial testing budesonide in Chronic Rhinosinusitis With Polyposis in 91 participants. Completed in 30 November 2017.

Timeline

1 January 2015

Primary endpoint
3 December 2016

30 November 2017

Quick facts

Lead sponsor	Beijing Tongren Hospital
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	91
Start date	1 January 2015
Primary completion	3 December 2016
Estimated completion	30 November 2017

Drugs / interventions tested

budesonide (BUDESONIDE) — full drug profile →
budesonide (BUDESONIDE) — full drug profile →
Prednisone (prednisone) — full drug profile →

Conditions studied

Chronic Rhinosinusitis With Polyposis — all drugs for Chronic Rhinosinusitis With Polyposis →

Sponsor

Beijing Tongren Hospital

Who can join

Adults 23 to 64, any sex, with Chronic Rhinosinusitis With Polyposis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Topical and systemic steroids constitute the first choice in medical treatment for nasal polyps. This study aimed to evaluate the efficacy and safety of a short course of budesonide inhalation suspension via transnasal nebulization in the preoperative management of chronic rhinosinusitis with nasal polyposis. The second aim was to compare budesonide inhalation suspension with budesonide aqueous nasal spray and oral prednisone in nasal polyp treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Comparison of Corticosteroids by 3 Approaches to the Treatment of Chronic Rhinosinusitis With Nasal Polyps.
Zhang Y, Lou H, Wang Y, Li Y, et al · · 2019 · cited 25× · PMID 31172717 · DOI 10.4168/aair.2019.11.4.482

Verify or expand the search:

Other trials of budesonide

Trials testing the same drug.

NCT06595121 — Bioequivalence of IMP 08P1707F0 Relative to Pulmicort® (1.0 Mg/2 Ml Suspension) · Phase 1 · completed
NCT06719622 — Evaluation of the Efficacy of Local Budesonide Treatment in Children with Crohn's Disease Located in the Esophagus And/o · Phase 2, PHASE3 · enrolling by invitation
NCT06841406 — Budesonide as a Treatment for Functional Dyspepsia · Phase 4 · recruiting
NCT05839756 — Predicting Post Extubation Stridor After Maxillomandibular Fixation · NA · recruiting
NCT03275415 — Intratracheal Budesonide/Surfactant Prevents BPD · Phase 4 · completed

Other Beijing Tongren Hospital trials

Trials by the same sponsor.

NCT07499791 — Absorbable Drug-Eluting Lacrimal Sac Stent for Recurrent Chronic Dacryocystitis · Phase 2 · not yet recruiting
NCT07524959 — Antagonism of Neostigmine in Continuous Infusion of Mivacurium · NA · not yet recruiting
NCT07525466 — Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatm · Phase 1, PHASE2 · recruiting
NCT07472764 — Auricular Acupressure for Reducing Postoperative Emergence Agitation in Preschool Children · NA · not yet recruiting
NCT07523737 — Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Dif · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03687515 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Tongren Hospital
Last refreshed: 27 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03687515.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing